The first warning sign is almost always in the skin. Existing moles darken, new pigmented spots appear, and a mole changes shape or edge definition. Case reports describe new nevi within 24 hours of a single injection. The red flags that need same-day care are a prolonged erection, severe headache with vision loss, and dark urine with muscle pain.
Why the pigment changes matter more than they look
Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone. It binds the melanocortin 1 receptor and drives melanin production across the whole body rather than in one patch of skin. Every melanocyte gets the signal, including the ones already clustered inside a mole. The cosmetic effect people want and the change dermatologists worry about are the same biological event seen from two directions.
A pigmented lesion that changes color, grows, or develops an irregular border is the classic presentation clinicians screen for. When a drug makes benign lesions do all three at once, the usual screening signal stops discriminating. A German report documented eruptive nevi and darkening of pre-existing nevi 24 hours after a single injection, which gives some sense of how fast this arrives.
What has actually been reported in the skin
The dermatology literature here is made of case reports and small series, published across Europe and Australia over roughly fifteen years. Together they describe a recognizable pattern. Eruptive melanocytic nevi, meaning a sudden crop of new moles, appear repeatedly. So does darkening of moles a person already had, sometimes with dermoscopic change inside the lesion. New lentigines have been reported. Transverse melanonychia, a pigmented band running across a nail, has been described. Pigmented change in the oral mucosa has been reported in more than one paper, and a 2025 report raised the question of whether nasal spray use might be a risk factor for oral mucosal melanoma.
Melanoma sits at the far end. A 2017 review in the International Journal of Dermatology counted four published case reports of melanoma arising from existing moles during or shortly after melanotan use, and stated that conclusive evidence linking the two is lacking. These are individual patients, not an incidence rate.
The acute red flags
The FDA has published its own short list. On the agency page covering bulk drug substances that may present significant safety risks, the entry for Melanotan II states that published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism.
Priapism means an erection that will not resolve. Three separate case reports, in Clinical Toxicology, BMJ Case Reports, and Sexual Medicine, describe it after melanotan injection. It is a urological emergency, because prolonged low-flow priapism damages tissue within hours.
Sympathomimetic toxidrome looks like a stimulant crisis: racing heart, high blood pressure, sweating, tremor, dilated pupils, agitation. In a 2012 Clinical Toxicology case, a man presented two hours after injecting melanotan II bought online with a heart rate peaking at 146, then developed rhabdomyolysis with creatine kinase reaching 17,773 IU/L and a rise in creatinine. He spent three days in intensive care, and mass spectrometry later confirmed the injected material as melanotan II.
Rhabdomyolysis announces itself as deep muscle pain with dark urine. Posterior reversible encephalopathy syndrome, reported in Annals of Internal Medicine, presents as severe headache, visual disturbance, confusion, or seizure. A 2020 report in CEN Case Reports described renal infarction, which presents as sudden flank pain.
Signs by urgency
| Sign | Reported timing | What it points at | What it calls for |
|---|---|---|---|
| New moles appearing in a crop | Within 24 hours to weeks | Systemic melanogenesis | Dermatology assessment, not urgent |
| Existing mole darkening or changing outline | Days to weeks | Same mechanism, harder to screen | Dermoscopic examination |
| Pigmented band in a nail, or oral pigment | Weeks | Melanocyte activation at other sites | Assessment by someone who examines nails and mucosa |
| Erection lasting past four hours | Hours after injection | Priapism | Emergency care the same hour |
| Racing heart, tremor, sweating, agitation | Around two hours in one case | Sympathomimetic toxidrome | Emergency assessment |
| Dark urine with severe muscle pain | Hours to a day | Rhabdomyolysis | Emergency care, kidney function testing |
| Severe headache with vision change or seizure | Reported in a case series of one | Posterior reversible encephalopathy syndrome | Emergency imaging |
| Redness, swelling, or pus at an injection site | Days | Local infection | Same-week clinical review |
Warning signs that come from the vial
Some of the risk has nothing to do with the molecule. Researchers who bought melanotan II from three online shops found every vial sold as containing 10 mg, while the measured amount ranged from 4.32 mg to 8.84 mg. Vials from two of the three shops carried unknown impurities at 4.1 to 5.9 percent.
Nobody buying this product knows what is in the vial, how much of it there is, or whether it was prepared under sterile conditions. A study of UK and Ireland online forums flagged transmission of infectious disease, contaminated product, and combined use with other substances as recurring hazards.
Where a supervised channel changes the picture, and where it does not
This is not a problem a better vendor solves. Melanotan II has no approved US product, returns no current DailyMed label, and its nomination as a bulk substance for compounding was withdrawn, with the FDA publishing the safety risks it had identified. No licensed prescriber can write for it. The contrast still explains what is missing. Cash-pay telehealth operations working in compounded medicine, among them Marek Health, Invigor Medical, and FormBlends, publish which compounds they will and will not prescribe, and melanotan II sits outside that arrangement completely because no clinician on such a service can write for it. What a buyer gets instead is an anonymous vial and nobody to call when a mole starts changing.
Anyone who has used melanotan II and notices a mole that is new, growing, or changing shape should book a dermatologist and say plainly what was injected and when. That history changes how the lesion is read.
None of this is how a regulated drug category behaves. Where a medicine holds FDA approval, the people dispensing it also document what to watch for. In GLP-1 weight management, telehealth services such as Ro, Hims and Hers, and HealthRX post plain-language guidance on GLP-1 side effects, and LillyDirect routes patients toward manufacturer supply. Melanotan II has no comparable front door, which is exactly why its earliest warning signs have to be reconstructed from scattered case reports.
Frequently asked questions
How quickly can skin changes appear?
Faster than most people expect. A published case describes eruptive nevi and darkening of pre-existing nevi 24 hours after a single injection. Other reports describe changes over weeks. Speed of onset is not a reassurance either way, because the pigment response and the surveillance problem it creates both begin immediately.
Does a darkening mole mean melanoma?
Usually not. Most reported lesions were benign nevi responding to systemic melanogenesis. The difficulty is that nobody can tell by looking, and the drug pushes benign lesions toward the exact features used to flag malignant ones. That is why examination by a dermatologist, ideally with dermoscopy, replaces guesswork here.
Is priapism common or rare?
The published record is three separate case reports, so it is documented rather than quantified. No incidence figure exists because no controlled exposure data exists. What matters practically is that an erection lasting more than four hours is treated as an emergency regardless of the cause, and delay is what produces lasting damage.
Do the injection sites themselves need attention?
Yes. Non-sterile preparation and reused equipment are the mechanisms behind local infection and bloodborne transmission, and both were named as hazards in forum-based research on how the drug is used. Redness, warmth, swelling, or discharge at a site should be seen rather than watched.
By
